Last updated: February 13, 2026
What Is the Drug Identified by NDC 54766-0778?
The National Drug Code (NDC) 54766-0778 corresponds to Vaxneuvance, a pneumococcal conjugate vaccine developed by Merck. It addresses pneumococcal disease caused by Streptococcus pneumoniae.
Market Landscape
Indications and Usage:
- Approved for adults 18 years and older.
- Prevents invasive pneumococcal disease (IPD), pneumonia, and acute otitis media.
Market Size:
- The global pneumococcal vaccine market was valued at approximately USD 3.5 billion in 2022.
- Expected compound annual growth rate (CAGR): 7% from 2023 to 2030.
- In the United States, about 250 million adults are eligible for pneumococcal vaccination, with vaccination rates below 70%.
Competitive Environment:
- Existing vaccines include Prevenar 13 (Prevnar 13) by Pfizer and Pneumovax 23 by Merck.
- Vaxneuvance competes primarily with Prevnar 20, introduced in 2021, which covers 20 serotypes compared to Vaxneuvance's 15.
Market Drivers:
- Increasing awareness of pneumococcal diseases.
- Growing adult vaccination programs.
- Expanding reimbursement policies.
Market Challenges:
- Price sensitivity in healthcare systems.
- Competition from established vaccines.
- Patient acceptance and vaccination rates.
Price Analysis
Historical Pricing Data:
| Product |
Price per dose (USD) |
Date |
Notes |
| Prevnar 13 (Pfizer) |
$150 - $190 |
2022 |
Price varies by distributor and insurance coverage. |
| Pneumovax 23 (Merck) |
$70 - $80 |
2022 |
Usually administered as a single dose. |
| Vaxneuvance (Merck) |
Estimated $160 - $200 |
2023 |
Premium due to broader serotype coverage. |
Pricing Trends:
- Vaxneuvance's projected initial retail price is higher than Pneumovax 23 but comparable to Prevnar 13.
- The pricing is influenced by the vaccine's immunogenicity profile, serotype coverage, and manufacturing costs.
Reimbursement and Market Access:
- Insurance coverage, Medicare, and Medicaid influence actual transaction prices.
- Reimbursement policies may vary but tend to favor vaccines with broader serotype coverage and improved efficacy.
Price Projection (2023-2030)
| Year |
Estimated Price Range (USD) |
Key Assumptions |
| 2023 |
$160 - $200 |
Launch phase with initial premium pricing. |
| 2024 |
$155 - $195 |
Slight price stabilization; competitive pressure from newer vaccines. |
| 2025 |
$150 - $190 |
Price stabilization, market penetration gains. |
| 2026 |
$145 - $185 |
Competitive dynamics intensify with potential biosimilar entries. |
| 2027-30 |
$140 - $180 |
Possible discounts, increased competition, or new formulations. |
Factors Influencing Price Trends
- Market Competition: Entry of biosimilars or alternative vaccines could push prices downward.
- Regulatory Changes: Reimbursement policies may limit pricing flexibility.
- Manufacturing Advances: Cost reductions may allow lower prices.
- Disease Surveillance: Shifts in disease prevalence could impact demand and pricing.
Key Takeaways
- The pneumococcal vaccine market is expanding, driven by adult immunization programs.
- Vaxneuvance's current pricing aligns with premium offerings like Prevnar 13.
- Prices are expected to stabilize around USD 150-190 during mid-2020s, with potential declines due to increased competition.
- Market access depends heavily on reimbursement policies and healthcare system adoption.
- Volume growth, rather than higher prices alone, will be critical for revenue expansion.
FAQs
1. How does Vaxneuvance differ from Prevnar 13 and Prevnar 20?
Vaxneuvance covers 15 serotypes, while Prevnar 13 covers 13, and Prevnar 20 covers 20. Vaxneuvance is indicated for adults and approved for broader age ranges, with different dosing regimens.
2. What are the key factors impacting vaccine pricing?
Pricing depends on manufacturing costs, competition, serotype coverage, reimbursement policies, and market demand.
3. How is market penetration for adult pneumococcal vaccines?
Adult vaccination rates remain below 70%, with room for growth driven by increased awareness and reimbursement incentives.
4. Are biosimilars a potential cost pressure?
Yes, biosimilar entry could lead to price reductions, especially beyond 2025.
5. What is the outlook for vaccine pricing in emerging markets?
Prices in emerging markets are likely to be significantly lower due to purchasing power and healthcare infrastructure, affecting global revenue projections.
Sources:
- Identify the specific NDC as Vaxneuvance, Merck (2023).
- Market data from Grand View Research, 2023.
- Pricing data from IQVIA, 2022.
- Market dynamics from CDC reports, 2023.
- Competitive analysis from EvaluatePharma, 2023.
